Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −Highlights Phase 2 data for ATH434 in Multiple System ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today issued ...
Biogen Inc forecast 2026 profit above Wall Street’s expectations, signalling that steep cost-cutting measures are cushioning ...
Dagens.com on MSN
This sleep habit could be an early dementia warning
Acting out dreams linked to later cognitive decline.
After witnessing my father’s tortuous battle with the illness I wanted to understand my own risk, so I visited a brain expert ...
ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...
FDA approvals, trial progress and early commercial momentum put several ASX healthcare companies in a strong position heading ...
After years of misdiagnosis, Rod Fussinger was finally diagnosed with Anti-IgLON5 Associated Autoimmune Encephalitis, and ...
Death row intensifies the structured brutalities of the penal system and reminds us why the struggle against the death penalty must also include the fact of prison violence ...
The thymus peptide upregulated 1,198 genes tied to energy metabolism, DNA repair, and cell cycle regulation. The Thymus ...
For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results